U.S. markets open in 1 hour 30 minutes

Voyager Therapeutics, Inc. (VYGR)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
6.93-0.54 (-7.23%)
At close: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Williams %R

Williams %R

Previous Close7.47
Bid0.00 x 2900
Ask0.00 x 900
Day's Range6.50 - 7.40
52 Week Range2.46 - 10.60
Avg. Volume268,440
Market Cap267.828M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.87
Earnings DateOct 31, 2022 - Nov 04, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.60
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for VYGR

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Voyager Therapeutics, Inc.
    Analyst Report: Amgen Inc.Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
    Fair Value
    Economic Moat
    2 days agoMorningstar
View more
  • Benzinga

    Voyager Therapeutics Prioritizes Pipeline With Cash Runway Into 2024

    Voyager Therapeutics Inc (NASDAQ: VYGR) unveiled its prioritized therapeutic pipeline focusing on tau antibody for Alzheimer's disease and gene therapies for GBA1 Parkinson's and SOD1 ALS. For GBA1 Parkinson's, a non-human primate (NHP) capsid evaluation study is currently underway. Voyager intends to select a development candidate in 1H of 2023, initiate a dose range finding study in NHPs in 2H of 2023, and initiate GLP toxicology studies in 2024. Voyager anticipates an IND filing in 2025. For

  • Zacks

    Voyager Therapeutics (VYGR) Reports Q2 Loss, Misses Revenue Estimates

    Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of 10.71% and 71.52%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Voyager Therapeutics Prioritizes Pipeline and Reports Second Quarter 2022 Financial and Operating Results

    Pipeline prioritizes tau antibody for Alzheimer's disease and gene therapies for GBA1 Parkinson's disease and SOD1 ALS, each program employing efficient paths to human proof of biology Targeting development candidate selection for priority programs in 2022 and H1 2023 Cross species transduction for multiple capsids and characterization of the receptor for a leading capsid support human translation potential of TRACERTM capsids Catherine J. Mackey, Ph.D., appointed to Board of Directors Strong ba